Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 4/20 | 0.57 |
| ▸ | CAMKK2 | Q96RR4 | 4/20 | 0.57 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | ITK | Q08881 | 1/20 | 0.52 |
| ▸ | AXL | P30530 | 5/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2181151 | 0.85 | BTK (0.45) | SGK1CAMKK2BTKITKAXL | |
| SCHEMBL8314581 | 0.84 | SGK1 (0.62) | SGK1CAMKK2BTKITKAXL | |
| SCHEMBL24369420 | 0.77 | SGK1 (0.67) | SGK1CAMKK2AXLNEK1 | |
| SCHEMBL8313454 | 0.75 | SGK1 (0.58) | SGK1CAMKK2BTKITKAXL | |
| SCHEMBL8320227 | 0.75 | KIT (0.67) | AAK1DYRK1AMAP3K11 | |
| SCHEMBL10607787 | 0.73 | CA1 (0.61) | KDM4E | |
| SCHEMBL12829259 | 0.73 | NTRK1 (0.66) | SGK1AXLBRD4CLK1DYRK1A | |
| SCHEMBL20408723 | 0.73 | KIT (0.59) | SGK1CAMKK2AXLBRD4CLK1 | |
| SCHEMBL8320542 | 0.73 | DYRK1A (0.59) | AXLBRD4AAK1CLK1DYRK1A | |
| SCHEMBL1800807 | 0.72 | AXL (0.73) | SGK1CAMKK2AXLMAP3K11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295433-A2 | JNK inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | SGK1 198/4885CAMKK2 94/4885BTK 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.